Press release dated November 04, 2026, titled "Press Release on financial results for the quarter and…
As filed · Biocon Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Press Release on financial results for the quarter and half-year ended September 30, 2026".
What happened
FactA press release dated November 04, 2026, titled "Press Release on financial results for the quarter and half-year ended September 30, 2026". please find enclosed the press release titled “Biocon Q2FY27 Total Income at Rs 4,423 Cr; EBITDA at Rs 865. Cr; Net Profit at Rs 41 Cr; Biopharma Revenue Up 5%” pertaining to the un-audited consolidated financial.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Market Share
WithdrawnThis is a $9 billion opportunity.
It is really up to us to take this market share in a very responsible manner so that we can provide options to patients for a very, very long time.
Change
FactImplication
CapitSignal interpretationDemand
ContradictedTotal insulin franchise globally is crossed $300 million.
Adalimumab globally, again, is beyond $250 million.
Change
FactImplication
CapitSignal interpretationDemand
RevisedFrom a dollar number perspective, I think we can get you the numbers, but it will be around at $7 billion, $8 billion overall insulin.
RHI is about $1.5 billion globally, and you'll see the other 2 be in the region of about $3 billion.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Looking ahead, we remain focused on the strategic expansion of our differentiated GLP-1 portfolio into new mar (management committed by FY26)
- the focus has always been to see that we have a new product launch either in the US or in Europe every year fr (management committed by FY27)
Evidence
- Biocon Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Press Release on financial results for the quarter and half-year ended September 30, 2026".(opens the original filing in a new tab)
- Earlier statement · Q4 FY25
- Latest statement · Q2 FY26
- Earlier statement · Q4 FY26
- Latest statement · Q4 FY26
- Earlier statement · Q4 FY26
- Latest statement · Q4 FY26
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%